The PE Ratio as of November 2024 (TTM) for Fate Therapeutics, Inc. (FATE) is -1.40

According to Fate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.40. This represents a change of -46.52% compared to the average of -2.62 of the last 4 quarters.

Fate Therapeutics, Inc. (FATE) Historical PE Ratio (quarterly & annually)

How has FATE PE Ratio performed in the past?

The mean historical PE Ratio of Fate Therapeutics, Inc. over the last ten years is -11.67. The current -1.40 PE Ratio has changed 1.10% with respect to the historical average. Over the past ten years (40 quarters), FATE's PE Ratio was at its highest in in the September 2023 quarter at -1.16. The PE Ratio was at its lowest in in the March 2021 quarter at -42.71.

Fate Therapeutics, Inc. (FATE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Fate Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Fate Therapeutics, Inc. (FATE) Average PE Ratio

How has FATE PE Ratio performed in the past?

The current PE Ratio of Fate Therapeutics, Inc. (FATE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Fate Therapeutics, Inc. (FATE) PE Ratio vs. Peers

How is FATE’s PE Ratio compared to its peers?

Fate Therapeutics, Inc.’s PE Ratio is less than Atara Biotherapeutics, Inc. (-0.09), greater than Sana Biotechnology, Inc. (-2.01), less than Caribou Biosciences, Inc. (-1.23), greater than Arcus Biosciences, Inc. (-4.98), greater than Intellia Therapeutics, Inc. (-2.77), less than Editas Medicine, Inc. (-0.96), greater than CRISPR Therapeutics AG (-17.03), greater than Verve Therapeutics, Inc. (-2.07), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than aTyr Pharma, Inc. (-2.33), greater than Relay Therapeutics, Inc. (-1.93), less than Century Therapeutics, Inc. (-0.79), greater than Blueprint Medicines Corporation (-46.60), greater than Beam Therapeutics Inc. (-14.38), greater than Prime Medicine, Inc. (-1.75),

Build a custom stock screener for Fate Therapeutics, Inc. (FATE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Fate Therapeutics, Inc. (FATE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Fate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.